试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-12-11
To Assess Efficacy of Nutritional Therapy in Secondary Prophylaxis of Hepatic Encephalopathy Versus Lactulose in Patients With Liver Cirrhosis.
编号:NCT03161106登记状态:入组前撤回企业 / 申办者:Institute of Liver and Biliary Sciences, India
药物 / 成分:Nutrition、Lactulose、Diet
登记的停止原因(原文):due lack of funds
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-12-11
Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents
编号:NCT03349346登记状态:入组前撤回企业 / 申办者:Gilead Sciences
药物 / 成分:Idelalisib、Rituximab、Ifosfamide、Carboplatin
登记的停止原因(原文):The European Medical Agency granted a Paediatric Investigational Product-specific waiver on the grounds that idelalisib is likely to be unsafe in paediatrics
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-12-10
Proton Pump Inhibitor Therapy for Mild to Moderate Obstructive Sleep Apnea
编号:NCT00211614登记状态:入组前撤回企业 / 申办者:MetroHealth Medical Center
药物 / 成分:Lansoprazole
登记的停止原因(原文):No enrollment.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-12-07
Comparison Efficacy of 14-day Concomitant Therapy:Clarithromycin vs.Levofloxacin in Eradication of H.Pylori
编号:NCT03021590登记状态:入组前撤回企业 / 申办者:Damascus Hospital
药物 / 成分:Clarithromycin 500Mg Oral Tablet、Levofloxacin 500Mg Oral Tablet
登记的停止原因(原文):No Participants Enrolled
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-12-07
Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary Hypertension
编号:NCT03309592登记状态:入组前撤回企业 / 申办者:Ochsner Health System
药物 / 成分:Ambrisentan Pill、Tadalafil Pill
登记的停止原因(原文):Lack of eligible participants and failure to meeting study enrollment.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-12-07
Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer
编号:NCT03419130登记状态:入组前撤回企业 / 申办者:University of California, San Francisco
药物 / 成分:Hypofractionated Radiation Therapy、Laboratory Biomarker Analysis、Pembrolizumab、Radiation Therapy
登记的停止原因(原文):Study withdrawn prior to patient enrollment
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-12-07
Human Lysozyme Goat Milk in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
编号:NCT03531281登记状态:入组前撤回企业 / 申办者:City of Hope Medical Center
药物 / 成分:Allogeneic Hematopoietic Stem Cell Transplantation、Cyclophosphamide、Etoposide、Goat Milk
登记的停止原因(原文):Administratively withdrawn
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-12-06
Xolair (Omalizumab) for Treatment of Drug-induced Acute Tubulointerstitial Nephritis (AIN)
编号:NCT01893658登记状态:入组前撤回企业 / 申办者:Mayo Clinic
药物 / 成分:Omalizumab、Prednisone
登记的停止原因(原文):Lack of patients with a condition of interest that resulted in failure to recruit
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-12-04
Phase 3, Randomized, Safety, Lot Consistency and Clinical Benefit Study of Recombinant Botulinum Vaccine A/B
编号:NCT01940315登记状态:入组前撤回企业 / 申办者:DynPort Vaccine Company LLC, A GDIT Company
药物 / 成分:rBV A/B、Placebo (USP sterile saline for injection)
登记的停止原因(原文):Sponsor decision due to product manufacturing and redesign of clinical trial.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-12-04
Clinical and Financial Impact of an Evidenced-Based Adhesive Small Bowel Obstruction Management Protocol
编号:NCT02928458登记状态:入组前撤回企业 / 申办者:The Guthrie Clinic
药物 / 成分:Omnipaque、MD-Gastroview
登记的停止原因(原文):Inadequate enrollment
查看官方原始记录 ↗